Speece Thorson Capital Group’s Zimmer Biomet ZBH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$12.8M Sell
141,354
-13,824
-9% -$1.27M 2.91% 18
2025
Q4
$14M Sell
155,178
-44,313
-22% -$4.2M 3.02% 16
2025
Q3
$19.6M Sell
199,491
-2,319
-1% -$230K 3.93% 3
2025
Q2
$18.4M Buy
201,810
+23,049
+13% +$2.23M 3.75% 6
2025
Q1
$20.2M Sell
178,761
-3,039
-2% -$325K 4.17% 2
2024
Q4
$19.2M Sell
181,800
-950
-0.5% -$102K 3.79% 4
2024
Q3
$19.7M Sell
182,750
-534
-0.3% -$58.3K 3.64% 3
2024
Q2
$19.9M Buy
183,284
+27,127
+17% +$3.2M 4.07% 3
2024
Q1
$20.6M Sell
156,157
-2,045
-1% -$255K 3.98% 2
2023
Q4
$19.3M Buy
158,202
+19,144
+14% +$2.14M 3.95% 5
2023
Q3
$15.6M Sell
139,058
-153
-0.1% -$19.4K 3.44% 8
2023
Q2
$20.3M Sell
139,211
-56,644
-29% -$7.7M 4.15% 2
2023
Q1
$25.3M Sell
195,855
-20,190
-9% -$2.53M 5.33% 1
2022
Q4
$27.5M Hold
216,045
5.91% 1
2022
Q3
$22.6M Buy
216,045
+24,116
+13% +$2.65M 5.15% 2
2022
Q2
$20.2M Buy
191,929
+20,442
+12% +$2.43M 4.75% 3
2022
Q1
$21.9M Buy
171,487
+4,852
+3% +$585K 4.69% 3
2021
Q4
$20.6M Buy
166,635
+74,925
+82% +$9.81M 3.93% 5
2021
Q3
$13M Sell
91,710
-57
-0.1% -$8.38K 2.73% 17
2021
Q2
$14.3M Sell
91,767
-489
-0.5% -$79.2K 2.99% 16
2021
Q1
$14.3M Sell
92,256
-568
-0.6% -$88K 3.02% 16
2020
Q4
$13.9M Buy
92,824
+7,515
+9% +$1.06M 3.3% 11
2020
Q3
$11.3M Buy
85,309
+449
+0.5% +$58.7K 2.99% 16
2020
Q2
$9.83M Sell
84,860
-1,049
-1% -$121K 2.83% 17
2020
Q1
$8.43M Buy
85,909
+17,405
+25% +$2.28M 2.9% 15
2019
Q4
$9.96M Sell
68,504
-541
-0.8% -$74.7K 2.58% 16
2019
Q3
$9.2M Sell
69,045
-15,401
-18% -$1.99M 2.46% 18
2019
Q2
$9.65M Buy
84,446
+17,145
+25% +$2.01M 2.57% 17
2019
Q1
$8.34M Sell
67,301
-615
-0.9% -$69.9K 2.3% 21
2018
Q4
$6.84M Sell
67,916
-7,665
-10% -$862K 2.05% 25
2018
Q3
$9.65M Sell
75,581
-8,493
-10% -$1.01M 2.24% 26
2018
Q2
$9.1M Buy
84,074
+33,534
+66% +$3.65M 1.92% 26
2018
Q1
$5.35M Sell
50,540
-3,492
-6% -$406K 1.14% 39
2017
Q4
$6.33M Sell
54,032
-411
-0.8% -$46.5K 1.26% 37
2017
Q3
$6.19M Sell
54,443
-19,914
-27% -$2.3M 1.29% 36
2017
Q2
$9.27M Buy
74,357
+358
+0.5% +$42.4K 1.93% 29
2017
Q1
$8.77M Buy
73,999
+2,057
+3% +$233K 1.86% 32
2016
Q4
$7.21M Buy
71,942
+4,207
+6% +$451K 1.61% 34
2016
Q3
$8.55M Sell
67,735
-11,538
-15% -$1.43M 1.83% 31
2016
Q2
$9.27M Buy
79,273
+1,095
+1% +$124K 2.01% 27
2016
Q1
$8.09M Buy
78,178
+1,188
+2% +$115K 1.82% 28
2015
Q4
$7.67M Buy
76,990
+473
+0.6% +$46.3K 1.87% 27
2015
Q3
$6.98M Buy
76,517
+23,062
+43% +$2.31M 1.74% 30
2015
Q2
$5.67M Sell
53,455
-402
-0.7% -$44.5K 1.36% 32
2015
Q1
$6.14M Buy
53,857
+742
+1% +$84.7K 1.44% 32
2014
Q4
$5.85M Sell
53,115
-783
-1% -$82.5K 1.42% 33
2014
Q3
$5.26M Buy
53,898
+2,534
+5% +$249K 1.34% 33
2014
Q2
$5.18M Sell
51,364
-31,858
-38% -$3.11M 1.32% 36
2014
Q1
$7.64M Sell
83,222
-15,687
-16% -$1.45M 2.01% 26
2013
Q4
$8.95M Sell
98,909
-1,588
-2% -$137K 2.37% 20
2013
Q3
$8.01M Sell
100,497
-1,504
-1% -$118K 2.22% 24
2013
Q2
$7.42M Buy
+102,001
New +$7.63M 2.16% 21

Other funds holding ZBH

Speece Thorson Capital Group's ZBH Position: Q1 2026 in Review

Speece Thorson Capital Group reduced its Zimmer Biomet (ZBH) stake by 8.9% in Q1 2026, selling an estimated $1.27M and leaving 141,354 shares worth $12.8M. The position accounts for 2.91% of the portfolio, ranked #18.

Speece Thorson Capital Group first reported a position in ZBH in Q2 2013 and has held it in 52 quarters since. The position peaked at $27.5M in Q4 2022. 912 funds tracked by Wall St. Rank hold ZBH as of Q1 2026.

  • Speece Thorson Capital Group held 141,354 shares of Zimmer Biomet worth $12.8M as of Q1 2026.
  • Speece Thorson Capital Group sold 13,824 Zimmer Biomet shares in Q1 2026, an estimated $1.27M.
  • Zimmer Biomet made up 2.91% of Speece Thorson Capital Group's portfolio in Q1 2026, its #18 holding.
  • Speece Thorson Capital Group first reported a position in Zimmer Biomet in Q2 2013 and has held it in 52 quarters since.
  • Speece Thorson Capital Group's Zimmer Biomet position peaked at $27.5M in Q4 2022.
  • 912 funds tracked by Wall St. Rank held Zimmer Biomet as of Q1 2026.

Based on Speece Thorson Capital Group's 13F filing for Q1 2026, filed 29 Apr 2026.